Cover Image

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Hankey, Graeme (Author) , Hacke, Werner (Author)
Format: Article (Journal)
Language:English
Published: March 7, 2012
In: The lancet
Year: 2012, Volume: 11, Issue: 4, Pages: 315-322
ISSN:1474-4465
DOI:10.1016/S1474-4422(12)70042-X
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/S1474-4422(12)70042-X
Verlag, Volltext: http://linkinghub.elsevier.com/retrieve/pii/S147444221270042X
Get full text
Author Notes:Graeme J Hankey, Manesh R Patel, Susanna R Stevens, Richard C Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A Donnan, Jonathan L Halperin, Kenneth W Mahaffey, Jean-Louis Mas, Ayrton Massaro, Bo Norrving, Christopher C Nessel, John F Paolini, Risto O Roine, Daniel E Singer, Lawrence Wong, Robert M Califf, Keith AA Fox, Werner Hacke, for the ROCKET AF Steering Committee and Investigators
Description
Summary:Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).
Item Description:Gesehen am 24.07.2018
Physical Description:Online Resource
ISSN:1474-4465
DOI:10.1016/S1474-4422(12)70042-X

Similar Items